Regards on Flumazenil: Unlocking Wakefulness in Idiopathic Hypersomnia

Welcome to “Regards on Flumazenil,” a blog series where we decode the science behind this fascinating compound and explore what we’ve learned from some of the top experts in the field. Join us as we dig into flumazenil and the conditions it’s being used to treat, drawing on the best resources we could find. Today we’re looking at what came out of the Hypersomnia Foundation’s conference talk, “Conventional (and Not-So-Conventional) Treatments for Idiopathic Hypersomnia,” given by Dr. Lynn Marie Trotti.

Unlocking Wakefulness: Exploring Treatments for Idiopathic Hypersomnia

Idiopathic hypersomnia (IH) is a chronic sleep disorder that most people have never heard of, and because of that, it’s often written off as laziness or depression rather than what it actually is: a neurological condition. In a recent talk, Dr. Lynn Marie Trotti, a neurologist who has spent much of her career studying sleep, walked through the messy, evolving picture of IH treatment, including the barriers patients run into and where the research is actually headed.

One of the more interesting threads she pulled on was flumazenil, a drug that’s normally used to reverse a benzodiazepine overdose, and its emerging role as a possible treatment for IH. Since there’s still no FDA-approved medication built specifically for this condition, any option that shows promise, even a repurposed one, matters a great deal to people who’ve been stuck with unrelenting daytime sleepiness for years.

Dr. Trotti is an Associate Professor of Neurology at Emory University and one of the more visible researchers working on hypersomnia today. In her talk, she walked through both the well-established treatments and the stranger, lesser-known ones. Let’s go through what she covered and unpack how each option fits into the bigger picture.

If you want to go deeper on IH itself, the Hypersomnia Foundation has a solid overview built for patients.

What Is Idiopathic Hypersomnia?

Idiopathic hypersomnia is not just being tired. It’s a neurological disorder marked by excessive daytime sleepiness that doesn’t go away even after a full night of sleep, or in many cases, after 10, 12, or 14 hours of sleep. People living with IH often can’t stay awake through a normal day, and that has real consequences for work, school, relationships, and just about everything else.

So how is this different from narcolepsy? Unlike narcolepsy type 1, IH doesn’t come with cataplexy, the sudden loss of muscle tone that’s triggered by strong emotion. Diagnosis is genuinely difficult because it leans on a mix of subjective tools, like the Epworth Sleepiness Scale, and objective testing, like the Multiple Sleep Latency Test (MSLT). Neither one tells the whole story on its own. In fact, research reviewed by the Hypersomnia Foundation shows that repeating the MSLT can produce different results in the same person over time, which is part of why IH and narcolepsy type 2 sometimes get confused with each other, or misdiagnosed entirely.

For more on symptoms and how doctors reach a diagnosis, the Hypersomnia Foundation’s IH page is a good starting point.

The Treatment Gap: Why Are There So Few Options?

Here’s the frustrating part. No medication currently carries FDA approval specifically for idiopathic hypersomnia. That means everything a doctor prescribes for IH is technically “off-label,” meaning the drug was approved for something else and is being used here based on clinical judgment and whatever evidence exists.

Off-label prescribing is common across medicine and isn’t inherently a red flag, but it does mean patients and doctors are working with less certainty. These treatments haven’t gone through the same rigorous, IH-specific approval process that a purpose-built drug would.

Borrowing from the Narcolepsy Playbook

With no IH-specific drugs on the market, doctors typically reach for medications that were approved for narcolepsy and adapt them for IH. These generally fall into three groups:

• Wake-promoting agents: non-amphetamine medications that help people stay alert.
• Amphetamine-based stimulants: medications that boost alertness and focus more directly.
• Sodium oxybate (Xyrem): a medication taken at night that’s meant to improve sleep quality and reduce daytime sleepiness.

Not every sleep doctor is equally comfortable prescribing all three. Wake-promoting agents and stimulants tend to be the default starting point, with sodium oxybate held in reserve for cases where the first two don’t work well enough.

Modafinil and Armodafinil: Wake-Promoting Agents

Modafinil (Provigil) and armodafinil (Nuvigil) are non-amphetamine wake-promoting agents. They act on some of the same brain pathways as amphetamines but with a noticeably different side effect profile, which is a big part of why they’re usually tried first.

The first randomized controlled trial of modafinil for IH was actually run in Europe after regulators at the European Medicines Agency raised questions about the drug’s use in this population. That trial enrolled a mix of patients with IH and narcolepsy and used the Maintenance of Wakefulness Test (MWT), which measures how long someone can stay awake sitting in a dim, quiet room. Modafinil improved wakefulness, but patients still didn’t reach the same alertness levels as healthy, non-sleepy controls.

The same study also looked at driving performance using a simulator. Modafinil reduced lane drifting compared to placebo, though again, it didn’t fully close the gap with the control group.

A separate European study focused only on patients with IH without long sleep time. Researchers ended up lowering the modafinil dose because of side effects, and at that lower dose they couldn’t detect a statistically significant difference from placebo on the primary measure. That said, scores on the Epworth Sleepiness Scale still improved, which suggests the drug was doing something even if the trial wasn’t fully powered to prove it.

Modafinil vs. Armodafinil: What’s the Difference?

Modafinil isn’t a single molecule. It’s actually a combination of two mirror-image compounds, similar to how your left and right hands are mirror images of each other. Armodafinil is essentially the “right-handed” half of modafinil, isolated on its own.

The main practical difference comes down to duration. Armodafinil tends to last longer in the body, which is why some people can take it once a day, while modafinil is more often split into two daily doses.

There isn’t a dedicated randomized controlled trial of armodafinil in IH specifically, but because of the chemical overlap with modafinil, most clinicians assume the effects are broadly similar.

Modafinil: Does It Work in the Real World?

Clinical series, essentially large retrospective look-backs at how patients actually did on a medication, tell us something trials can’t: how well a drug holds up over months or years of real use, and how many people stick with it.

One such series followed roughly 200 IH patients treated with modafinil and found that about two-thirds stayed on the medication long-term. That’s a genuinely encouraging number, but it also means a meaningful share of patients needed something else entirely.

What About Traditional Stimulants?

When modafinil or armodafinil don’t cut it, doctors sometimes move to amphetamine-based stimulants, like Adderall, Dexedrine, or Vyvanse, the same class of drugs used to treat ADHD.

There are no randomized controlled trials of stimulants specifically in IH. What exists is a handful of small clinical series:

• Methylphenidate: in a series of 61 patients, roughly 40% stayed on the medication with good results.
• Amphetamine/dextroamphetamine: in a series of just 8 patients, about 25% continued with good results.
• Dextroamphetamine alone: in a series of 15 patients, roughly a third continued with good results.

Those are small numbers, and they underline just how much more research this area still needs.

What If Nothing Works? The Unmet Need

A meaningful portion of people with IH simply don’t respond well to modafinil, armodafinil, or stimulants. Others respond but can’t tolerate the side effects. That gap is exactly why researchers keep circling back to the more experimental options below.

Venturing into the Unconventional

From here, we’re moving into treatments that aren’t considered standard of care. They’re not right for everyone, and some have much thinner evidence behind them than others. Everything covered below has at least been documented somewhere in the medical literature.

Sodium Oxybate: A Surprising Option

Sodium oxybate (Xyrem) is FDA-approved for narcolepsy. It’s taken in two doses, one at bedtime and a second a few hours later, and it’s designed to deepen sleep quality overnight while reducing daytime sleepiness.

For a long time, doctors were hesitant to use it in IH patients specifically, since people with IH already sleep unusually deeply and often struggle badly with sleep inertia, that grogginess that makes waking up feel almost impossible. The worry was that deepening sleep even further might make that inertia worse.

A study out of Dr. Isabelle Arnulf’s group in France pushed back on that assumption. Researchers reviewed roughly 40 IH patients who’d been started on sodium oxybate after other treatments had failed, and the full chart review was published in Sleep Medicine. Compared to narcolepsy patients on the same drug, the IH patients generally needed lower doses to see benefit. Despite that, they experienced similar improvements in daytime sleepiness. More surprising still, sleep inertia actually got better for many of these patients rather than worse. Close to half of the group stayed on sodium oxybate long-term.

Sodium Oxybate: Dose Timing and Waking Up

The practical catch with sodium oxybate is the second dose. Patients have to wake themselves up in the middle of the night to take it, and for people with IH, waking up on command is often the exact thing they struggle with most. As a result, plenty of patients end up skipping or delaying that second dose, which means they’re effectively getting less medication than intended.

Clarithromycin: An Unexpected Discovery

Clarithromycin is a common antibiotic, and using it for a sleep disorder sounds strange at first. But there’s a real mechanism behind it.

Researchers, including Dr. Trotti’s own team, believe GABA receptors play a central role in IH, and clarithromycin appears to interact with those receptors in a way that reduces sleepiness. A randomized, crossover trial tested this directly. Trotti and colleagues published the results in the Annals of Neurology, enrolling patients with IH, narcolepsy without cataplexy, and IH with a normal MSLT. Everyone stayed on their existing medications throughout. Reaction time didn’t improve, which surprised the researchers, but clarithromycin did produce a meaningful improvement in Epworth Sleepiness Scale scores, along with gains in daily functioning and overall well-being. An earlier open-label clinical series from the same group had shown similar improvements in daytime sleepiness, which helped justify running the more rigorous crossover trial.

Clarithromycin: A Necessary Evil?

The obvious downside is that clarithromycin is still an antibiotic. Long-term use raises real concerns about antibiotic resistance, along with GI upset and an unpleasant taste that a lot of patients report. There’s a clear need for something that hits the same GABA mechanism without carrying those risks, which is part of what makes flumazenil interesting.

Flumazenil: Targeting GABA Receptors More Directly

Flumazenil goes after GABA receptors more directly than clarithromycin does. It’s FDA-approved, but only for reversing benzodiazepine overdoses, the kind of emergency use you’d see in a hospital, not for long-term daily treatment of anything.

When flumazenil is given intravenously to IH patients, it reduces sleepiness for roughly two hours. Obviously, nobody can run IV infusions every couple of hours as an ongoing treatment, so compounding pharmacies have stepped in to create versions that patients can actually use day to day.

Oral flumazenil doesn’t work well on its own because the liver metabolizes most of it before it ever reaches the bloodstream, a problem pharmacologists call first-pass metabolism. To get around that, two compounded formulations have become the standard workaround:

• Topical cream, applied to the forearms, where veins sit close to the skin’s surface.
• Sublingual lozenges, dissolved under the tongue, where the medication can absorb directly into the bloodstream without passing through the liver first.

Flumazenil: Cream vs. Sublingual Lozenge

The cream works because the veins in the forearm are close enough to the surface that the drug can be absorbed transdermally, bypassing the digestive system entirely. Sublingual lozenges rely on a similar principle, using the dense network of blood vessels under the tongue to get the medication into circulation quickly.

Flumazenil: Clinical Experience and Outcomes

The very first patient treated with flumazenil for hypersomnolence recently marked her tenth year on the medication, which says something on its own about how it can work for the right patient. More formally, Dr. Trotti and colleagues reviewed the charts of the first 153 patients treated with flumazenil at Emory, publishing their findings in the Journal of Clinical Sleep Medicine. Of those patients, 63% reported feeling less sleepy after starting the drug. Interestingly, the response rate skewed by sex, with about 72% of women reporting benefit compared to roughly 48% of men. Even so, only 39% of patients were still using flumazenil by the end of the review period, which averaged just under seven months.

Patients who stopped cited a mix of reasons: the drug simply not working well enough, side effects, cost (since compounded formulations usually aren’t covered by insurance), and in some cases, tolerance building up over time. A 39% long-term continuation rate isn’t a home run, but for patients who’ve already burned through modafinil, stimulants, and sodium oxybate without relief, it can be a meaningful option.

Levothyroxine: A Thyroid Hormone Approach

Levothyroxine is standard thyroid hormone replacement therapy. Since thyroid hormone plays a role in wakefulness, some researchers have asked whether giving extra thyroid hormone might help IH patients, even when their thyroid function tests come back completely normal.

A case series out of Japan looked at nine IH patients with long sleep times and normal thyroid function. Treatment with levothyroxine led to real improvements in both sleepiness and overall sleep duration.

Dr. Trotti has been candid that her own clinical experience hasn’t matched those dramatic results. She’s suggested this might come down to differences in how IH presents across patient populations, or possibly just less collective experience using levothyroxine this way outside of that one study. It may still be worth trying for some patients, but it clearly isn’t a universal fix.

Brain Stimulation: A Glimmer of Hope?

Transcranial direct current stimulation (tDCS) is a non-invasive technique that applies mild electrical current to the scalp to influence activity in the underlying brain tissue.

In a small case series of eight previously untreated IH patients, tDCS led to a meaningful drop in reported sleepiness, and seven of the eight patients said they felt better on the treatment, with measurable gains on an attention test. A clinical trial is currently underway to test tDCS more rigorously in IH, and it should give a much clearer picture of whether these early results hold up.

It’s worth being cautious here. Eight patients is a tiny sample, and all of them were treatment-naive going in, which tends to inflate response rates compared to a more treatment-resistant population.

Looking Ahead: The Future of Idiopathic Hypersomnia Treatment

We’ve covered a lot of ground here, from well-studied stimulants to genuinely experimental approaches like brain stimulation. New clinical trials continue to explore fresh angles on IH, and the field is moving, even if slowly.

Dr. Trotti’s work, and the platform the Hypersomnia Foundation gives it, points to something worth remembering: there’s no cure for IH yet, but the research base keeps growing. Every study, every off-label experiment that gets formally written up, adds one more data point that future patients and doctors can actually use.

Flumazenil captures that spirit well. It offers real, if temporary and imperfect, relief for some patients, and it’s a good example of how medicine sometimes advances by repurposing an old, overlooked drug rather than waiting for something entirely new.

Closing Thoughts

Dr. Trotti’s talk laid out the real texture of living with IH: the misconceptions, the stigma, and the frustratingly thin menu of treatment options. IH remains underdiagnosed and poorly understood, and a lot of patients spend years just trying to get someone to take their symptoms seriously.

Flumazenil is one of the more promising threads in current research, targeting the GABA system directly to counter excessive sleepiness. But access is a real barrier. Compounded formulations are expensive, often not covered by insurance, and not every pharmacy can make them. Larger trials are still needed before flumazenil could move beyond off-label, specialist-driven use. Other areas of research, including dietary interventions, the gut microbiome, and immune-related mechanisms, may open up entirely new treatment paths down the line.

Beyond medications, awareness and advocacy do a lot of the heavy lifting here. Better education, both for healthcare providers and the public, is what actually chips away at the stereotype that IH is just laziness or poor sleep hygiene. Groups like the Hypersomnia Foundation are pushing on all of this at once: research funding, public recognition, and direct support for patients trying to navigate a system that doesn’t always know what to do with them.

The road ahead for IH treatment looks genuinely more promising than it did even a decade ago. In the meantime, progress depends on patients, clinicians, and advocacy organizations continuing to push together.

About Dr. Lynn Marie Trotti

Dr. Lynn Marie Trotti is an Associate Professor of Neurology at Emory University and Chair of the Medical Advisory Board for the Hypersomnia Foundation. Her research has focused heavily on hypersomnia and related sleep disorders, including much of the clinical work on flumazenil and clarithromycin referenced above. Her studies have helped bring long-overlooked treatment options into the open, giving both clinicians and patients more to work with than the standard narcolepsy playbook alone.

This blog post is for informational purposes only and doesn’t constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment of any medical condition.

Supporting the Hypersomnia Foundation

If this was helpful, consider donating to the Hypersomnia Foundation to support their research, education, and advocacy work for people living with IH.

Engage with the Hypersomnia Community

What treatments have actually helped you manage IH symptoms? Share your experience in the comments below.

FAQ: Idiopathic Hypersomnia and Flumazenil

1. What is idiopathic hypersomnia (IH)? IH is a neurological sleep disorder marked by excessive daytime sleepiness despite getting what should be adequate, or even prolonged, nighttime sleep. Unlike narcolepsy, it doesn’t involve cataplexy, and it’s often accompanied by severe sleep inertia, sometimes called “sleep drunkenness.”

2. How is IH different from narcolepsy? IH and narcolepsy type 2 (narcolepsy without cataplexy) both cause severe daytime sleepiness, but IH tends to come with longer sleep duration, unrefreshing naps, and much harder waking. Narcolepsy more often involves fragmented nighttime sleep, and type 1 specifically includes cataplexy.

3. What are the symptoms of IH?

• Excessive daytime sleepiness (EDS)
• Difficulty waking up in the morning (sleep inertia)
• Long, unrefreshing naps
• Brain fog and cognitive difficulty
• Persistent fatigue

4. How is IH diagnosed? Diagnosis usually involves a clinical evaluation, a detailed sleep history, and objective testing through polysomnography (PSG) followed by a Multiple Sleep Latency Test (MSLT), which measures how quickly someone falls asleep in a controlled setting.

5. What is flumazenil and how does it work for IH? Flumazenil is FDA-approved for reversing benzodiazepine overdose. In IH, researchers believe it works by counteracting excessive GABA activity that may be contributing to constant sleepiness. It’s available in IV form in clinical settings, and compounded into sublingual lozenges or topical creams for ongoing outpatient use.

6. Is flumazenil effective for IH? Clinical data from Dr. Trotti’s review found that 63% of patients reported some benefit, and 39% stayed on the medication long-term. Results vary a lot from patient to patient, and it’s generally reserved for people who haven’t responded to more conventional treatments.

7. What are the side effects of flumazenil? Common side effects include dizziness, nausea, headaches, and temporary anxiety. It isn’t right for every patient, and it should only be started under the guidance of a sleep specialist familiar with its off-label use in hypersomnia.

8. How is flumazenil administered for IH? Since oral flumazenil is broken down too quickly by the liver, patients typically use:

• Sublingual lozenges, dissolved under the tongue
• Topical cream, applied to the forearm
• IV infusion, generally reserved for clinical or diagnostic settings

9. What other off-label treatments are used for IH?

• Clarithromycin, an antibiotic that also affects GABA receptors
• Levothyroxine, a thyroid hormone treatment with mixed results
• Transcranial direct current stimulation (tDCS), a non-invasive brain stimulation method still being studied

10. Can lifestyle changes help manage IH symptoms? Medication is usually necessary, but some patients find that a consistent sleep schedule, avoiding alcohol and sedating medications, strategic napping, and light therapy help take the edge off symptoms alongside treatment.

11. Is IH a lifelong condition? For most people, yes. IH is generally chronic, though symptom severity can shift over time. Long-term management, usually a combination of medication and behavioral strategies, is typically needed.

12. Where can I find more information and support for IH? The Hypersomnia Foundation is the best starting point, with research updates, a healthcare provider directory, and community support resources for people living with IH.